Abstract:Background: The global burden of non-alcoholic fatty liver disease (NAFLD) is growing, but its subsequent health consequences have not been thoroughly examined. We performed phenome-wide Mendelian randomization and disease-trajectory analyses to comprehensively assess the health outcomes of NAFLD.Methods: PheWAS analyses were conducted to map the associations of NAFLD with a broad range of phenotypes among 475,554 European in UK Biobank. Disease-trajectory and comorbidity analyses were applied to visualize the sequential patterns of multiple comorbidities related to the occurrence of NAFLD. The associations jointly verified by observational and polygenic PheWAS analyses were further replicated by two-sample MR analysis using data from the FinnGen study and international consortia.Findings: PheWAS analyses including 1,172 disease outcomes revealed the associations of NAFLD diagnosis (n=9,035) with intrahepatic (e.g., cirrhosis, liver abscess and liver cancer) and extrahepatic diseases, including circulatory diseases (i.e., various cardiac diseases, hypertension and cerebrovascular diseases), metabolic diseases (i.e., hyperlipidemia and diabetes mellitus), genitourinary system diseases (i.e., renal failure), neurological disorders (i.e., dementias and Alzheimer's disease), gastrointestinal diseases (i.e., gastritis, duodenitis and ulcerative colitis, stomach cancer and other malignant digestive neoplasms) and hematologic diseases (i.e., iron deficiency anemia and thrombocytopenia). Disease-trajectory and comorbidity network analyses identified 3 major extrahepatic comorbidities clusters related to NAFLD, mainly in cardiovascular, metabolic, and inflammatory diseases. Two-sample MR analyses supported the causal associations between NAFLD and the risk of several intrahepatic disorders, metabolic diseases, cardio-cerebro-vascular disease and ascites, but found no associations with neurological diseases (i.e., dementia).Interpretation: A prior diagnosis of NAFLD was associated with an increased risk of various extrahepatic diseases of circulatory, metabolic, genitourinary, gastrointestinal and possibly neurological systems. Three major sequential patterns of comorbidities related to NAFLD were identified, mainly in cardiovascular, metabolic and inflammatory diseases, contributing to development of combination interventions targeting distinct pathways for the health promotion among NAFLD patients.Funding: XL: the Natural Science Fund for Distinguished Young Scholars of Zhejiang Province (LR22H260001) and the National Nature Science Foundation of China (N0. 82204019); SCL: the Swedish Heart-Lung Foundation (Hjärt-Lungfonden, 20210351), the Swedish Research Council (Vetenskapsrådet, 2019-00977), and the Swedish Cancer Society (Cancerfonden).Declaration of Interest: All authors report no potential conflicts of interest.Ethical Approval: Ethical approval was granted by the UK Biobank by the North West-Haydock Research Ethics Committee (REC reference: 16/NW/0274).

Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia

Multisystem Health Comorbidity Networks of Nonalcoholic Fatty Liver Disease: Phenome-Wide Mendelian Randomization and Disease-Trajectory Analyses

Multisystem health consequences of nonalcoholic fatty liver disease: phenome-wide Mendelian randomization and disease-trajectory analyses

Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective.

Genetics Is of the Essence to Face NAFLD

Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk

Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD

From Pathogenesis to Current Therapeutic Options

Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review

NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options

Metabolic Associated Fatty Liver Disease in Children and Adolescents: Mechanisms of a Silent Epidemic and Therapeutic Options

Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD

Expanding the p.(Arg85Trp) Variant-Specific Phenotype of HNF4A: Features of Glycogen Storage Disease, Liver Cirrhosis, Impaired Mitochondrial Function, and Glomerular Changes

The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment

Transmembrane 6 Superfamily Member 2 Gene Variant Disentangles Nonalcoholic Steatohepatitis from Cardiovascular Disease

Gut Microbiota in NAFLD Pathogenesis and Possible Dietary-Based Strategies

Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis

Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making

Serum mitochondrial bioenergetics as fingerprint of the hepatic one: how to monitor genetic MASLD

Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link